Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1–selected advanced non–small-cell lung cancer (BIRCH)
…, LQM Chow, M Koczywas, C Ho, M Früh… - Journal of Clinical …, 2017 - ascopubs.org
Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed
death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung …
death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung …
Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data
…, RM Rudd, H Okamoto, DV Skarlos, M Früh… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Since treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-line
treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of …
treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of …
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with …
…, L Flatz, D Born, W Jochum, AJ Templeton, M Früh - Lung cancer, 2017 - Elsevier
Objectives Immunotherapy with the programmed death receptor-1 (PD-1) antibody
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) treatment. …
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) treatment. …
SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non–small-cell lung cancer—a multicenter single-arm phase II trial
…, D Betticher, A Bettini, M Früh… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE For patients with resectable stage IIIA(N2) non–small-cell lung cancer, neoadjuvant
chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-…
chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-…
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
…, W Weder, S Thierstein, MA Gerard, A Xyrafas, M Früh… - The Lancet, 2015 - thelancet.com
Background One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung
cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate …
cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
…, M Campana, O Gautschi, M Früh… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
Management of stage III non–small-cell lung cancer: ASCO guideline
…, E David, F Detterbeck, M Früh… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An Expert …
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An Expert …
[HTML][HTML] Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry
…, V Velcheti, K Zeidler, J Diebold, M Früh… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are
driven by less common genomic alterations, registries provide complementary information on …
driven by less common genomic alterations, registries provide complementary information on …
Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer
…, M Recher, J Goldman, A Cozzio, M Früh… - JAMA …, 2019 - jamanetwork.com
Importance Immunotherapy with checkpoint inhibitors targeting the PD-1 (programmed cell
death 1) axis has brought notable progress in patients with non–small cell lung cancer (…
death 1) axis has brought notable progress in patients with non–small cell lung cancer (…
[HTML][HTML] Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort
Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma
viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, …
viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, …